Menu Search
Equities

Precigen Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
I5X:FRA

Precigen Inc

Actions
  • Price (EUR)4.06
  • Today's Change0.312 / 8.33%
  • Shares traded600.00
  • 1 Year change+141.72%
  • Beta1.0629
Data delayed at least 15 minutes, as of Feb 12 2026 07:41 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

  • Revenue in USD (TTM)6.31m
  • Net income in USD-425.87m
  • Incorporated2004
  • Employees143.00
  • Location
    Precigen Inc20374 SENECA MEADOWS PARKWAYGERMANTOWN 20876United StatesUSA
  • Phone+1 (301) 556-9900
  • Websitehttps://precigen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.